



Original article

Influence of gender on Behçet's disease phenotype and irreversible organ damage: Data from the International AIDA Network Behçet's Disease Registry[☆]



Jurgen Sota^a, Gaafar Ragab^{b,c}, Ibrahim AlMaglouth^d, Giuseppe Lopalco^e, Abdurrahman Tufan^f, Haner Direskeneli^g, Andrea Hinojosa-Azaola^h, Henrique Ayres Mayrink Giardiniⁱ, Silvana Guerriero^j, Paola Triggianese^k, Petros P. Sfikakis^l, Matteo Piga^m, Piero Ruscittiⁿ, Marcello Govoni^o, Annamaria Iagnocco^p, Francesco Carubbi^q, José Hernández-Rodríguez^r, Ahmed Hatem Laymouna^b, Ayman Abdel-Monem Ahmed Mahmoud^b, Mahmoud Ghanema^b, Aos A. Aboabat^d, Kazi Nur Asfina^d, Fehaid Alanazi^d, Maria Morrone^e, Veronica Spedicato^e, Hamit Kucuk^f, Riza Kardas^f, Fatma Alibaz Öner^g, Gizem Sevik^g, Jiram Torres-Ruiz^h, Perla Ayumi Kawakami-Campos^h, Isabelle Parente de Brito Antonelliⁱ, Rosanna Dammacco^j, Maria Sole Chimenti^k, Katerina Arida^l, Alberto Floris^m, Martina Gentileⁿ, Francesca Ruffilli^o, Elisa Bellis^p, Alessia Alunno^q, Gerard Espinosa^r, Stefano Gentileschi^a, Carla Gaggiano^a, Antonio Vitale^a, Valeria Caggiano^a, Roberta Lopez^a, Maria Tarsia^a, Sara Monti^s, Gülen Hatemi^{t,u}, Alican Karakoç^t, Micol Frassi^v, Roberto Giacomelli^w, Samar Tharwat^{x,y}, Maissa Thabet^z, Francesco Ciccia^{aa}, Giacomo Emmi^{ab,ac,ad}, Ombretta Viapiana^{ae}, Ali Şahin^{af}, Gian Domenico Sebastiani^{ag}, Ezgi Deniz Batu^{ah}, Seza Ozen^{ah}, Seher Sener^{ah}, Daniela Opris-Belinski^{ai}, Stefania Costi^{aj}, Alessandro Conforti^{ak}, Marco Cattalini^{al}, Elena Bartoloni^{am}, Nurullah Akkoç^{an}, Ozgul Soysal Gunduz^{an}, Giovanni Conti^{ao}, Armin Maier^{ap}, Annarita Giardina^{aq}, Francesca Li Gobbi^{ar}, Paola Parronchi^{as}, Piercarlo Sarzi Puttini^{at}, Luciana Breda^{au}, Amato De Paulis^{av,aw}, Ester Carreño^{ax}, Francesco La Torre^{ay}, Ewa Więsik-Sczewczyk^{az}, Alejandra de-la Torre^{ba}, Germán Mejía-Salgado^{ba}, Farhad Shahram^{bb}, Serena Guiducci^{bc}, Maria Cristina Maggio^{bd}, Emma Aragona^{be}, Donato Rigante^{bf,bg}, Alessandro Ciavarrò^{bh}, Fatos Önen^{bi}, Şükran Erten^{bj}, Antonella Insalaco^{bk}, Emanuela Del Giudice^{bl}, Patrizia Barone^{bm}, Francesca Gicchino^{bn}, Antonio Brucato^{bo}, Alberto Lo Gullo^{bp}, Angela Mauro^{bq,br}, Anastasios Karamanacos^{bs}, Alberto Balistreri^{bt}, Maria Antonietta Mazzei^{bu}, Bruno Frediani^a, Claudia Fabiani^{bv,1}, Luca Cantarini^{a,1,*}

^a Rheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences Department of Medical Sciences, Surgery and Neurosciences, University of Siena and Azienda Ospedaliero-Universitaria Senese [European Reference Network (ERN) for Rare Immunodeficiency, Autoinflammatory, and Autoimmune Diseases (RITA) Center], Siena, Italy

^b Rheumatology and Clinical Immunology Unit, Internal Medicine Department, Faculty of Medicine, Cairo University, Giza, Egypt

^c Faculty of Medicine, Newgiza University, 6th of October City, Egypt

^d Rheumatology Unit, Department of Medicine, King Saud University, Riyadh, Saudi Arabia

^e Department of Precision and Regenerative Medicine and Ionian Area (DiMePre-J), Policlinic Hospital, University of Bari, Bari, Italy

^f Division of Rheumatology, Department of Internal Medicine, Gazi University Hospital, Ankara, Turkey

^g Department of Internal Medicine, Division of Rheumatology, School of Medicine, Marmara University, Istanbul, Turkey

^h Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

[☆] From the International AIDA (AutoInflammatory Diseases Alliance) Network and from the Autoinflammatory Diseases Working Group of the Italian Society of Rheumatology (SIR).

* Corresponding author.

Adresse e-mail : cantariniluca@hotmail.com (L. Cantarini).

¹ These authors equally contributed.

- ⁱ Rheumatology Division, Faculdade de Medicina, Hospital das Clinicas (HCFMUSP), Universidade de Sao Paulo, Sao Paulo, Brazil
- ^j DiBrain department, University of Bari, Bari, Italy
- ^k Rheumatology, Allergy and Clinical Immunology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
- ^l Joint Academic Rheumatology Program, National and Kapodistrian University of Athens Medical School, [European Reference Network (ERN) for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (RITA) Center], Athens, Greece
- ^m Rheumatology Unit, Department of Medical Sciences and Public health, University and AOU of Cagliari, Cagliari, Italy
- ⁿ Rheumatology Unit, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy
- ^o Rheumatology Unit, Department of Medical Sciences, Azienda Ospedaliero-Universitaria S. Anna-Ferrara, University of Ferrara, Ferrara, Italy
- ^p Academic Rheumatology Center, Dipartimento Scienze Cliniche e Biologiche, Università degli Studi di Torino, Turin, Italy
- ^q University of L'Aquila, Department of Life, Health & Environmental Sciences, Internal Medicine and Nephrology Division, ASL1 Avezano-Sulmona-L'Aquila, San Salvatore Hospital, L'Aquila, Italy
- ^r Autoinflammatory Diseases Clinical Unit, Department of Autoimmune Diseases, Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Center of the European Reference Network (ERN) for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (RITA), Barcelona, Spain
- ^s Rheumatology Department, IRCCS Policlinico S. Matteo Fondazione, University of Pavia, [European Reference Network (ERN) for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (RITA) Center], Pavia, Italy
- ^t Department of Internal Medicine, Division of Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey
- ^u Behçet's Disease Research Center, Istanbul University-Cerrahpasa, Istanbul, Turkey
- ^v Rheumatology and Clinical Immunology, Spedali Civili and Department of Clinical and Experimental Sciences, University of Brescia, [European Reference Network (ERN) for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (RITA) Center], Brescia, Italy
- ^w Rheumatology, Immunology and Clinical Medicine Unit, Department of Medicine, Università Campus Bio-Medico di Roma, Rome, Italy
- ^x Rheumatology and Immunology Unit, Internal Medicine Department, Mansoura University, Mansoura, Egypt
- ^y Department of Internal Medicine, Faculty of Medicine, Horus University, New Damietta, Egypt
- ^z Internal Medicine Department, Farhat Hached University Hospital, Faculty of Medicine of Sousse, University of Sousse, Sousse, Tunisia
- ^{aa} Department of Precision Medicine, Università Degli Studi Della Campania Luigi Vanvitelli, Naples, Italy
- ^{ab} Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy
- ^{ac} Clinical Medicine and Rheumatology Unit, Cattinara University Hospital, Trieste, Italy
- ^{ad} Centre for Inflammatory Diseases, Monash University Department of Medicine, Monash Medical Centre, Melbourne, Australia
- ^{ae} Rheumatology Unit, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy
- ^{af} Division of Rheumatology, Department of Internal Medicine, Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey
- ^{ag} U.O.C. Reumatologia, Ospedale San Camillo-Forlanini, Rome, Italy
- ^{ah} Pediatric Rheumatology Unit, Department of Pediatrics, Hacettepe University School of Medicine, Ankara, Turkey
- ^{ai} Rheumatology and Internal Medicine Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
- ^{aj} Unit of Pediatric Rheumatology, Azienda Socio-Sanitaria Territoriale (ASST) Gaetano Pini-Centro Specialistico Ortopedico Traumatologico (CTO), Milan, Italy
- ^{ak} U.O. Medicina Generale, Ospedale San Paolo di Civitavecchia, ASL Roma 4, Civitavecchia, Rome, Italy
- ^{al} Pediatric Clinic, University of Brescia and Spedali Civili di Brescia [European Reference Network (ERN) for Rare Immunodeficiency, Autoinflammatory, and Autoimmune Diseases (RITA) Center], Brescia, Italy
- ^{am} Rheumatology Unit, Department of Medicine and Surgery, University of Perugia, Perugia, Italy
- ^{an} Division of Rheumatology, Department of Internal Medicine, School of Medicine, Manisa Celal Bayar University, Manisa, Turkey
- ^{ao} Pediatric Nephrology and Rheumatology Unit, Azienda Ospedaliero Universitaria (AOU) G Martino, Messina, Italy
- ^{ap} Rheumatology Unit, Department of Medicine, Central Hospital of Bolzano, Bolzano, Italy
- ^{aq} UOC Medicina Interna, Ambulatorio di Reumatologia, ARNAS Civico Di Cristina Benfratelli, Palermo, Italy
- ^{ar} Rheumatology Unit, San Giovanni di Dio Hospital, Firenze, Italy
- ^{as} Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
- ^{at} Rheumatology Unit, Ospedale Sacco, Milan, Italy
- ^{au} Department of Paediatrics, University of Chieti-Pescara, Chieti, Italy
- ^{av} Section of Clinical Immunology, Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy
- ^{aw} Department of Translational Medical Sciences, Center for Basic and Clinical Immunology Research (CISI), World Allergy Organisation Center of Excellence, University of Naples Federico II, Naples, Italy
- ^{ax} Department of Ophthalmology, Fundación Jiménez Díaz University Hospital (FJD), Madrid, Spain
- ^{ay} Department of Pediatrics, Giovanni XXIII Pediatric Hospital, University of Bari, Bari, Italy
- ^{az} Department of Internal Medicine, Pneumology, Allergy and Clinical Immunology, Central Clinical Hospital of the Ministry of National Defense, Military Institute of Medicine, National Research Institute, Warsaw, Poland
- ^{ba} Neuroscience Research Group (NEUROS), Neurovitae Center for Neuroscience, Institute of Translational Medicine (IMT), School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia
- ^{bb} Behçet's Disease Unit, Rheumatology Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
- ^{bc} Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
- ^{bd} University Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE) "G. D'Alessandro", University of Palermo, Palermo, Italy
- ^{be} Division of Gastroenterology, Ospedali Riuniti Villa Sofia-Vincenzo Cervello, Palermo, Italy
- ^{bf} Department of Life Sciences and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
- ^{bg} Rare Diseases and Periodic Fevers Research Centre, Università Cattolica Sacro Cuore, Rome, Italy
- ^{bh} Department of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata, Via Cracovia, 50, 00133 Rome, Italy
- ^{bi} Department of Internal Medicine, Division of Rheumatology, Dokuz Eylül University, School of Medicine, Izmir, Turkey
- ^{bj} Department of Rheumatology, Faculty of Medicine Ankara City Hospital, Ankara Yıldırım Beyazıt University, Ankara, Turkey
- ^{bk} Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS [European Reference Network (ERN) for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (RITA) Center], Rome, Italy
- ^{bl} Department of Maternal Infantile and Urological Sciences, Sapienza University of Rome, Polo Pontino, Rome, Italy
- ^{bim} Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy
- ^{bn} Department of Woman, Child and of General and Specialized Surgery, University of Campania "Luigi Vanvitelli", Naples, Italy
- ^{bo} Pediatric Unit, Fatebenefratelli Hospital, Milan, Italy
- ^{bp} UOSD Reumatologia, ARNAS Garibaldi, Catania, Italy
- ^{bq} Department of Biomedical and Clinical Sciences, Fatebenefratelli Hospital, Università di Milano, Milan, Italy
- ^{br} Pediatric Rheumatology Unit, Department of Childhood and Developmental Medicine, Fatebenefratelli-Sacco Hospital, Milan, Italy
- ^{bs} Department of Rheumatology, Evangelismos General Hospital, Athens, Greece
- ^{bt} Bioengineering and Biomedical Data Science Lab, Department of Medical Biotechnologies, University of Siena, [European Reference Network (ERN) for Rare Immunodeficiency, Autoinflammatory, and Autoimmune Diseases (RITA) Center], Siena, Italy
- ^{bu} Unit of Diagnostic Imaging, Department of Medical, Surgical and NeuroSciences and of Radiological Sciences, University of Siena, Azienda Ospedaliero-Universitaria Senese, [European Reference Network (ERN) for Rare Immunodeficiency, Autoinflammatory, and Autoimmune Diseases (RITA) Center], Siena, Italy
- ^{bv} Ophthalmology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena and Azienda Ospedaliero-Universitaria Senese [European Reference Network (ERN) for Rare Immunodeficiency, Autoinflammatory, and Autoimmune Diseases (RITA) Center], Siena, Italy

INFO ARTICLE

Historique de l'article :

Accepté le 30 octobre 2024

Disponible sur Internet le 15 November 2024

Keywords :

Behçet's disease

Gender

Registry

Autoinflammatory

Organ damage

ABSTRACT

Objectives. – Gender impact on phenotypical expression of Behçet's disease (BD) has been specifically investigated only in a few large-scale studies. The main goal of the study was to examine gender differences in a large cohort of patients affected by BD.

Methods. – Data were retrieved from the International AIDA Network Registry for BD. We assessed differences between males and females in terms of Behçet's syndrome Overall Damage Index (BODI), differences in the disease manifestations at onset and in the cumulative manifestations throughout disease course, as well as differences in the cardiovascular risk. Finally, predictive factors leading to major organ involvement were investigated.

Results. – In total, 1024 BD patients (567 males, 457 females) were enrolled in the study, with a male-to-female ratio of 1.24/1. Males displayed a significantly higher mean $\pm$ SD BODI (1.92 ± 2.09) at the last follow-up, compared to female patients (1.25 ± 1.87) ($P < 0.0001$). Uveitis ($P < 0.0001$) and vascular involvement ($P = 0.0076$) were significantly more frequent among males whereas female patients were significantly over-represented in arthralgia ($P < 0.0001$), arthritis ($P = 0.00025$), isolated headache ($P < 0.0001$), central nervous system (CNS) involvement ($P = 0.040$), and gastrointestinal involvement ($P = 0.00046$). Regarding cardiovascular risk, no differences between the two groups emerged ($P = 0.617$). Four variables were associated with the development of major organ involvement: male gender (OR = 2.104, $P = 0.001$), current treatment with biologic agents (OR = 2.257, $P = 0.0003$), origin from endemic countries (OR = 2.661, $P = 0.0009$), and disease duration (OR = 1.002, $P = 0.024$).

Conclusion. – BD displays a more severe course among males. This subgroup develops more irreversible damage and presents more frequently ocular and vascular involvement during disease course. On the other hand, female patients are prone to experience articular involvement, headache, CNS and gastrointestinal involvement. These data suggest the existence of a gender-driven disease expression.

© 2024 Les Auteurs. Publié par Elsevier Masson SAS au nom de Société Française de Rhumatologie. Cet article est publié en Open Access sous licence CC BY (<http://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Behçet's disease (BD) represents a multisystemic immune-mediated inflammatory disorder of uncertain etiology [1,2]. The complex and largely unknown pathogenesis is reflected in a highly heterogeneous clinical picture that may vary in each patient. Indeed, despite being originally described as the triple symptom complex comprising oral aphthous, genital ulcers and uveitis, virtually any organ could be involved [3–5]. The factors driving the heterogeneous phenotypical expression could lie on genetic background as testified by the marked geographical variability across countries. BD is particularly prevalent among the ancient “Silk Route” populations with a very high prevalence reported in Turkey (42 cases per 10,000 inhabitants) [6]. On the contrary, a lower prevalence has been detected in Western countries [7]. Regarding clinical features, the highest frequency of gastrointestinal involvement has been reported in Japan [8]. Similarly, pathergy test has shown a higher diagnostic accuracy in Middle East populations and considerably lower in other countries [9,10]. Gender and its effects on disease expression could be responsible for an additional influence on the already complex and protean clinical picture. Indeed, young males have been found to display a significantly higher mortality rate due to vascular and neurological involvement, as well as a higher morbidity in terms of visual prognosis [11–13].

The impact of gender in disease expression has been specifically investigated only in few large-scale studies [11,14–20]. We herein provide our multicentre experience on the influence of gender in BD from a large cohort of patients enrolled in the international Autoinflammatory Disease Alliance (AIDA) registry for BD with a particular focus on potential differences in long-standing damage accrual and disease phenotype.

2. Methods

2.1. Study population and participants

Data for the present study were retrieved from medical records of patients diagnosed with BD and enrolled in the international

AIDA Network for BD registry until January 9th, 2024. The registry is a clinical physician-driven and electronic-based instrument implemented for the retrospective and prospective collection of real-life data about demographics, clinical, therapeutic, laboratory, instrumental, and socioeconomic information from BD patients [21], and currently upholds data on more than 1076 patients (April 24th, 2024).

2.2. Data collection

The following demographic and clinical data were collected: gender, ethnicity, family history, age at onset, age at diagnosis, human leukocyte antigen (HLA)-B*51 typing, disease manifestations at disease onset, cumulative manifestations throughout disease course, clinical duration, Behçet's syndrome overall damage Index (BODI) recorded at last follow-up visit and cardiovascular risk data. Detailed treatment data for each follow-up visit were not retrieved for the purposes of this study. BODI consists of 34 items and 12 subitems, categorized into nine organ/system domains designed to assess the extent and type of organ damage accrual [22]. Age at disease onset was established as the age of the first disease-related clinical manifestation. The diagnostic delay was considered as the duration from the first disease-related manifestation to definite BD diagnosis, according to the International Study Group (ISG) criteria and/or International Criteria for Behçet's Disease (ICBD) [23,24]. BD-related uveitis was classified according to the Standardization of Uveitis Nomenclature criteria [25]. Vascular involvement included venous manifestations (thrombosis, superficial phlebitis) and arterial manifestations (aneurysm, stenosis, occlusion). Neuro-BD, both parenchymal and non-parenchymal, was detected by the rheumatologist and the dedicated neurologist according to the International Consensus on Neuro-BD of 2014, contemplating recognized neurological features, characteristic magnetic resonance imaging findings and/or cerebrospinal fluid findings [26], while unexplained isolated headache was analyzed separately. Similarly, abdominal pain without endoscopic evidence did not count as gastrointestinal involvement for inferential statistical analysis. Major organ involvement was defined

as the involvement of any one of the following systems: ocular, neurological, vascular, or gastrointestinal.

Patients with unspecified gender and/or insufficient registry data were excluded from the study. All patients were systematically followed up every 3-to-6 months or in case of necessity (disease flare and/or safety issues).

2.3. Aims and endpoints

The primary aim of the study was to estimate potential gender differences in the development of long-term irreversible organ damage. Secondary aims were to: (i) evaluate gender differences in the disease manifestations at onset and, cumulatively (from onset to the last follow-up visit), (ii) investigate potential gender differences in the cardiovascular risk, (iii) find predictive factor of major organ involvement and (iv) impact of gender in BD phenotypes divided in 5 clusters (mucocutaneous, articular, predominantly ocular, predominantly vascular, predominantly neurologic).

The primary endpoint was analyzed by potential statistical differences between male and female patients regarding the accrual of long-term damage measured with the BODI. Secondary endpoints were examined by any statistical differences between male and female patients in disease manifestations at onset and throughout the disease course, as well as in the cardiovascular risk. Cardiovascular risk was defined by the presence of any of the following: hypercholesterolemia, diabetes mellitus, excessive alcohol consumption, history of smoking, presence of arterial hypertension, cardiovascular events and body mass index higher than 30 kg/m². Predictive factors of major organ involvement and the influence of gender in disease clusters were identified via binary regression analysis.

2.4. Protocol approval

The present study was conducted according to the tenets of the Declaration of Helsinki and received approval from the local Ethics Committee of the University of Siena (Reference No. 14951). All patients or their legal guardians gave written informed consent.

2.5. Statistical analysis

Data were analyzed using IBMSPSS Statistics for Windows, version 28 (IBM Corp., Armonk, NY, US). Normality distribution of continuous variables was assessed with the Shapiro–Wilk test. Descriptive statistics was employed to calculate mean and standard deviation (SD) or median and interquartile range (IQR) as required. Cross-tables were analyzed by Pearson's Chi² test and post hoc test with adjusted residuals in case of contingency tables with dimensions greater than 2 × 2, while continuous variable were tested with the Mann–Whitney U test. Potential predictors of major organ involvement and the influence of gender in disease clustering were identified by binary logistic regression with the backward stepwise method and multinomial regression analysis, respectively. All tests were 2-sided and the threshold of statistical significance was set at 0.05.

3. Results

In total, 1024 patients with BD (567 males and 457 females) were enrolled in the study, with a male-to-female ratio of 1.24/1. The ethnic origin was composed mainly of Caucasian (*n*=640) and Arab (*n*=286) patients, followed by African (*n*=22), Hispanic (*n*=21) and Asian (*n*=14) patients, other (*n*=3), unspecified (*n*=38). Fig. 1 displays the cohort selection process and patients excluded from the study for insufficient data. The mean ± SD age at the onset of the entire cohort was 27.72 ± 12.44 years. Mean ± SD




Fig. 1. Chart showing the selection process for the cohort enrolled. AIDA: Autoinflammatory Disease Alliance; BD: Behçet's disease.

age at onset for males and females was 27.13 ± 14.80 years and 28.49 ± 20.20 years, respectively, without any statistically significant difference (*P*=0.092). The age distribution at onset according to pre-established age groups is illustrated in Fig. 2.

Oral aphthosis was the most frequent disease manifestation at onset (1004/1024, 98.05%), followed by genital ulcers (570/1024, 55.66%), skin lesions (529/1024, 51.66%) and intraocular inflammation (477/1024, 46.58%). Table 1 lists demographic and clinical features at disease onset and all the manifestations experienced throughout the disease course for the entire cohort. Table 2 details the same data separated by gender and their respective statistical significance. Female patients displayed a significantly older age at diagnosis (*P*<0.001), diagnostic delay (*P*<0.01) and disease duration (*P*<0.01). Additionally, HLA-B*51 positivity was significantly more frequent among female patients (*P*<0.001).

Male patients displayed a significantly higher BODI at the last follow-up than female patients (*P*<0.0001). Specifically, the mean ± SD [median (IQR)] BODI was 1.92 ± 2.09 [1.0 (3.0)] and 1.25 ± 1.87 [1.0 (2.0)] in males and females, respectively.

Regarding the influence of gender on disease manifestations experienced throughout the disease course, uveitis (*P*<0.001) and vascular involvement (*P*<0.01) were significantly more frequent among male patients whereas female patients were significantly over-represented in arthralgia (*P*<0.001), arthritis (*P*<0.001), isolated headache (*P*<0.001), and gastrointestinal involvement (*P*<0.001), central nervous system (CNS) involvement (*P*<0.05). The CNS involvement was subsequently separated into parenchymal and non-parenchymal form, revealing a statistically significant difference in the former (*P*<0.05), whereas no disparities were observed in non-parenchymal CNS involvement (*P*=0.543). Female patients were also inclined to display more frequently recur-




Fig. 2. Distribution of age at onset (expressed in years) separated by gender for Behçet's disease patients according to different age groups.

Table 1

Demographic data and clinical features at disease onset and during disease course of our cohort of BD patients.

Demographic features	
Male/female (n)	567/457
Mean age at onset $\pm$ SD (years)	27.72 $\pm$ 12.44
Mean age at diagnosis $\pm$ SD (years)	32.82 $\pm$ 12.50
Median (IQR) diagnostic delay (years)	4.72 (7.22)
Mean disease duration $\pm$ SD (years)	14.21 $\pm$ 10.45
HLA-B*51	411/795 (51.70%)
Clinical features at onset	
	n (%)
Oral aphthosis	938 (96.0)
Genital ulcers	570 (55.7)
Skin manifestations	529 (51.7)
Uveitis	477 (46.6)
Arthralgia	390 (38.1)
Arthritis	258 (25.2)
Vascular involvement	183 (17.9)
CNS	143 (14.0)
Abdominal pain	142 (13.9)
Cardiac involvement	21 (2.1)
Psychiatric manifestations	17 (1.7)
Clinical features throughout disease course	
	n (%)
Oral aphthosis	1004 (98.0)
Genital ulcers	589 (57.5)
Skin manifestations	584 (57.0)
Uveitis	528 (51.6)
Arthralgia	589 (57.5)
Arthritis	314 (30.7)
Vascular involvement	211 (20.6)
CNS	172 (16.8)
Isolated headache	300 (29.3)
Fever	213 (20.8)
Gastrointestinal involvement	233 (22.8)
	75 (7.3%) if only endoscopic lesions were considered
Cardiac involvement	42 (4.1)
Psychiatric manifestations	62 (6.1)

BD: Behçet's disease; CNS: central nervous system; HLA: human leukocyte antigen; IQR: interquartile range; SD: standard deviation.

Table 2

Frequency of clinical manifestations of BD patients occurring during disease course, stratified by gender.

	Male patients	Female patients
Mean age at onset $\pm$ SD (years)	27.13 $\pm$ 11.58	28.50 $\pm$ 13.46
Mean age at diagnosis $\pm$ SD (years)***	31.07 $\pm$ 11.47	35.04 $\pm$ 13.37
Median (IQR) diagnostic delay (years)**	1.40 (4.60)	2.00 (8.20)
Mean disease duration $\pm$ SD (years)**	10.92 $\pm$ 11.79	12.83 $\pm$ 15.31
HLA-B*51 positivity n (%)***	184 (43.60)	227 (60.85)
Clinical features at onset n (%)		
Oral aphthosis	544 (95.94)	439 (96.06)
Genital ulcers	303 (53.44)	267 (58.42)
Skin manifestations	297 (52.38)	232 (50.77)
Uveitis***	313 (55.20)	164 (35.89)
Arthralgia**	122 (21.52)	136 (29.76)
Arthritis***	175 (30.86)	215 (47.05)
Vascular involvement**	120 (21.16)	63 (13.79)
CNS (isolated headache included)*	67 (11.82)	76 (16.63)
Abdominal pain***	49 (8.64)	93 (20.35)
Cardiac involvement	12 (2.11)	9 (1.97)
Psychiatric manifestations	9 (1.59)	8 (1.75)
Clinical features throughout disease course n (%)		
Oral aphthosis	555 (97.88)	449 (98.25)
Genital ulcers	316 (55.73)	282 (61.71)
Skin manifestations	324 (57.14)	260 (56.89)
Uveitis***	334 (58.90)	194 (42.45)
Arthralgia***	274 (48.32)	315 (68.93)
Arthritis***	147 (25.92)	167 (36.54)
Vascular involvement**	134 (23.63)	77 (16.85)
CNS*	83 (14.63)	89 (19.47)
Isolated headache***	126 (22.22)	174 (38.07)
Fever**	100 (17.64)	113 (24.73)
Gastrointestinal involvement***	27 (4.76)	48 (10.50)
Cardiac involvement	19 (3.35)	23 (5.03)
Cardiovascular risk	367 (64.72)	280 (61.27)
Psychiatric manifestations	27 (4.76)	35 (7.66)

BD: Behçet's disease; CNS: central nervous system; HLA: human leukocyte antigen; IQR: interquartile range; SD: standard deviation

* $P < 0.05$.

** $P < 0.01$.

*** $P < 0.001$.

Table 3

Result from regression analysis for each variable included in the model alongside their respective *P*-values, odds ratios and confidence intervals.

Variable	<i>P</i> -value	Odds ratio	95% confidence interval
Gender	<0.001	2.104	1.353–3.273
Disease duration (years)	<0.05	1.002	1.0003–1.004
Ethnic origin	<0.001	2.661	1.494–4.738
Current treatment with biologic agents	<0.001	2.257	1.459–3.493

rent genital ulcers and psychiatric comorbidities with borderline statistically significant differences ($P=0.054$, $P=0.053$). A similar trend was also observed for clinical features at disease onset, with male patients reporting a significantly higher frequency of uveitis ($P<0.001$) and vascular involvement ($P<0.01$), whereas female patients were significantly more likely to present with arthralgia ($P<0.01$), arthritis ($P<0.001$), CNS involvement ($P<0.05$), abdominal pain ($P<0.001$). With reference to cardiovascular risk, 367 (64.73%) male patients and 280 (61.27%) female patients were considered at increased risk of cardiovascular events, without any statistically significant gender differences ($P=0.617$).

Four variables were associated with the development of major organ involvement during the disease course: male gender (OR=2.104, CI: 1.353–3.273, $P<0.01$), current treatment with biologic agents (OR=2.257, CI: 1.459–3.493, $P<0.001$), origin from endemic countries (OR=2.661, CI: 1.494–4.738, $P<0.001$) and disease duration (OR=1.002, CI: 1.0003–1.004, $P<0.05$). The findings regarding regression analysis are summarized in Table 3.

Male gender was significantly associated with the ocular and the vascular cluster ($P<0.001$, OR=2.853, CI: 1.615–5.039 and $P<0.05$, OR=2.293, CI: 1.050–5.007, respectively) while a longer disease duration (expressed in years), the absence of HLA-B*51 and a shorter diagnostic delay were significantly associated with the ocular cluster ($P<0.01$, OR=1.007, CI: 1.003–1.011, $P<0.05$, OR=0.517, CI: 0.329–0.990, $P<0.01$, OR=0.919, CI: 0.872–0.970, respectively).

Concerning treatment approach, conventional disease-modifying anti-rheumatic drugs were the most frequent prescribed therapy (49.23%), followed by colchicine (48.16%) and biologics (42.94%) variably combined between each other. The most frequent biologic employed were anti-tumor necrosis factor agents (92.86%).

4. Discussion

In the present international registry-based study, we have analyzed the demographic and clinical characteristics of a large cohort of BD patients focusing on potential gender differences. Our cohort was characterized by a heterogeneous ethnic origin and exhibited a slight male prevalence, with a male-to-female ratio of 1.24 to 1. Indeed, in studies with large sample sizes, gender distribution tends to equalize, approaching ratios reported in nationwide surveys [27,28]. The mean age at onset was 27.72 years, which is consistent with previous reports [29–31], indicating that disease usually outbreaks in the second or third decade of life. Similarly, the overall clinical picture of the present cohort of patients aligns with preceding studies [6,15,29,32], with mucocutaneous lesions as the most common features at disease onset, followed by uveitis, articular and vascular involvement.

Our data revealed several gender differences. Firstly, male patients displayed a significantly higher BODI assessed at the last follow-up visit. This finding becomes even more meaningful when considering a significantly shorter disease duration and a lower diagnostic delay in male patients enrolled in the AIDA registry. Therefore, it is plausible to assume that male patients carry a higher propensity of accumulating irreversible damage over time, despite a shorter disease duration and early diagnosis. Our findings are

consistent with a couple of studies exploring gender differences in relation to BODI, with one study revealing a higher BODI in males in univariate analysis [33], and the other one reporting male gender as associated with higher BODI values in multivariate analysis [34]. This aspect further supports the notion of a more severe course and poorer prognosis among males.

Regarding clinical manifestations, uveitis, and vascular involvement were significantly over-represented in male patients, both at disease onset and throughout disease course, while female patients exhibited more frequent articular involvement, CNS involvement and abdominal pain at disease onset. These data are consistent with previous large-scale studies reporting more frequent ocular and vascular involvement in male patients [12,15,35–37]. On the other hand, Davatchi et al., in a very large series of patients, while revealing statistically significant differences, found no strong association between the male gender and major organ involvement, except for vascular lesions. In fact, a strong association with an odds ratio > 2 was reported only for venous and arterial involvement [38].

Interestingly, the higher occurrence of gastrointestinal involvement during disease course persisted among females despite excluding abdominal pain and considering only lesions detected on endoscopic examination. The diagnostic delay and the consequent longer time-to-treatment, among females could be a contributing factor in the female predominance CNS and gastrointestinal involvement. Furthermore, gastrointestinal and CNS involvement are relatively late manifestations in BD. Finally, the sheer volume of data regarding endoscopically documented gastrointestinal involvement was low (27 males and 48 females). In this context, it is likely that a greater amount of data might nullify or even overturn this difference.

Female patients were also more likely to experience isolated headaches and fever during the whole disease course. Non-structural headaches, particularly tension-type headaches, have been reported with a significantly higher frequency in female patients affected by BD [39]. Also, a borderline significant tendency was observed toward genital ulcers and psychiatric manifestations throughout the disease course in female patients. It has been reported that patients presenting with mucocutaneous manifestations are less likely developing major organ involvement [37]. Therefore, a higher occurrence of genital lesions in females is potentially associated with the lower females' BODI score.

Taken together, these data indicate that several disease aspects appear to be gender-related and the gender-driven influence on disease phenotype is prominent. Male predominance in ocular and vascular involvement and female predominance of genital ulcer is a consistent finding in most of the available literature [11,12,15–20,35–37,40–46]. Similar results have been recently published by Kılıç et al. reporting a higher likelihood of ocular involvement and papulopustular lesions among male patients while a female predominance was shown in the occurrence of genital ulcers. The implementation of cluster analysis also in the context of gender-specific studies may potentially identify disease phenotypes, optimize treatment and ultimately lead to a personalized care [47]. In fact, our multinomial regression analysis found male gender significantly more prevalent in the ocular and vascular cluster, further supporting the male predominance in these disease phenotypes. The shorter diagnostic delay among male patients could also explain the association of a shorter diagnostic delay with the ocular cluster. Additionally, the relatively low prevalence of HLA-B*51 in the ocular cluster could be explained by the improvement in the diagnostic techniques and the improved knowledge in BD ocular manifestations that helps refer patients to the rheumatologist even in the absence of HLA-B*51.

Regarding gender differences in neurological and gastrointestinal involvement, data are more inconclusive and somewhat controversial [17,19,46–49]. Differences in design, in specific-organ

assessments and in therapeutic approach may account for the disparities encountered across studies.

Concerning potential predictors in the development of major organ involvement throughout the disease course, regression analysis identified the male gender among other variables, as independently and positively associated with the development of major organ involvement. This further supports the concept of a more severe course in male patients. Current treatment with biologic agents was another factor associated with major organ involvement. This is to be expected, since cases with a severe course have been treated more aggressively in order to minimize the detrimental long-term sequelae that would otherwise develop as disease progresses.

The underlying mechanisms in such notable gender differences in clinical phenotype, disease severity and prognosis may have a hormonal background. In this context, testosterone might play a pivotal role in disturbing neutrophil apoptosis in BD patients [50]. It appears to have a strong influence on neutrophil activation associated with significantly elevated levels of IL-2 and IL-12 in Th1 type immune response and marked downregulation of *IL-10* gene expression. Testosterone has also been associated with altered expression of Toll-like receptor 4, ERAP 1 and C-C motif of chemokine receptor 1 leading to Th1 polarization [51]. In addition to hormonal differences, the increased occurrence of vascular involvement in male patients could also be attributed to significantly higher homocysteine levels in this subgroup [52].

Despite providing robust real-life registry-based data, some limitations should be mentioned. First, The inherent nature of registry-based studies introduces several shortcomings including differences in patient management practices across centers, and the lack of standardized follow-up protocols. Secondly, we did not retrieve detailed descriptions of each manifestation as it was beyond the scope of the present study. In addition, the non-prospective collection for some of the variables precludes any assessment of causality or temporal relationship between them. For the same reason, therapeutic data and outcome measures related to treatment response were not retrieved. As a consequence, the impact of each therapeutic agent and its influence as a confounding factor were not assessed. Thirdly, while the heterogeneous cohort composed of different ethnic backgrounds allows to generalize our findings on one hand, makes it challenging to accurately establish gender-based differences in a firmly manner. Lastly, data for this study derive mainly from reference tertiary referral centers, which in turn collect patients with more severe disease thus generating a potential referral bias and missing a considerable portion of milder cases.

Whether gender is a major determinant in shaping the disease phenotype remains to be corroborated in future *ad-hoc* studies specifically designed to investigate each organ's involvement separately.

Funding

This study received funding from the patient advocacy organization S.I.M.B.A (Associazione Italiana Sindrome e Malattia di Behçet).

Disclosure of interest

The authors declare that they have no competing interest.

Références

- [1] Yazici Y, Hatemi G, Bodaghi B, Cheon JH, Suzuki N, Ambrose N, et al. Behçet syndrome. *Nat Rev Dis Primers* 2021;7:67, <http://dx.doi.org/10.1038/s41572-021-00301-1> [PMID: 34531393].
- [2] Emmi G, Bettiol A, Hatemi G, Prisco D. Behçet's syndrome. *Lancet* 2024;403:1093–108, [http://dx.doi.org/10.1016/S0140-6736\(23\)02629-6](http://dx.doi.org/10.1016/S0140-6736(23)02629-6).
- [3] Behçet H, Matteson EL. On relapsing, aphthous ulcers of the mouth, eye and genitalia caused by a virus. 1937. *Clin Exp Rheumatol* 2010;28:S2–5.
- [4] Emmi G, Prisco D. Behçet's syndrome: focus on pathogenetic background, clinical phenotypes and specific treatments. *Intern Emerg Med* 2019;14:639–43, <http://dx.doi.org/10.1007/s11739-019-02154-9>.
- [5] Hu D, She CH, Bao HF, Zou J, Cai JF, Ye JF, et al. Clinical heterogeneity and five phenotypes identified in pediatric Behçet's syndrome: a cohort study from Shanghai Behçet's syndrome database. *World J Pediatr* 2024;20:801–8, <http://dx.doi.org/10.1007/s12519-023-00785-9>.
- [6] Azizlerli G, Köse AA, Sarica R, Gül A, Tutkun IT, Kulaç M, et al. Prevalence of Behçet's disease in Istanbul, Turkey. *Int J Dermatol* 2003;42:803–6, <http://dx.doi.org/10.1046/j.1365-4362.2003.01893.x>.
- [7] Yurdakul S, Yazici H. Behçet's syndrome. *Best Pract Res Clin Rheumatol* 2008;22:793–809, <http://dx.doi.org/10.1016/j.berh.2008.08.005>.
- [8] Skef W, Hamilton MJ, Arayssi T. Gastrointestinal Behçet's disease: a review. *World J Gastroenterol* 2015;21:3801–12, <http://dx.doi.org/10.3748/wjg.v21.i13.3801>.
- [9] Friedman-Birnbaum R, Bergman R, Aizen E. Sensitivity and specificity of pathology test results in Israeli patients with Behçet's disease. *Cutis* 1990;45:261–4.
- [10] Davies PG, Fordham JN, Kirwan JR, Barnes CG, Dinning WJ. The pathology test and Behçet's syndrome in Britain. *Ann Rheum Dis* 1984;43:70–3, <http://dx.doi.org/10.1136/ard.43.1.70>.
- [11] Yazici H, Tüzün Y, Pazarli H, Yurdakul S, Ozyazgan Y, Özdoğan H, et al. Influence of age of onset and patient's sex on the prevalence and severity of manifestations of Behçet's syndrome. *Ann Rheum Dis* 1984;43:783–9, <http://dx.doi.org/10.1136/ard.43.6.783>.
- [12] Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamurudan V, et al. The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. *Medicine (Baltimore)* 2003;82:60–76, <http://dx.doi.org/10.1097/00005792-200301000-00006>.
- [13] Saadoun D, Wechsler B, Desseaux K, Le Thi Huong D, Amoura Z, Resche-Rigon M, et al. Mortality in Behçet's disease. *Arthritis Rheum* 2010;62:2806–12, <http://dx.doi.org/10.1002/art.27568>.
- [14] Davatchi F, Shahram F, Chams H, Nadji A, Jamshidi AR, Chams C, et al. The influence of gender on the severity and the outcome of ocular lesions in Behçet's disease. *Adv Exp Med Biol* 2003;528:67–71, <http://dx.doi.org/10.1007/0-306-48382-3.12>.
- [15] Bang DS, Oh SH, Lee KH, Lee ES, Lee SN. Influence of sex on patients with Behçet's disease in Korea. *J Korean Med Sci* 2003;18:231–5, <http://dx.doi.org/10.3346/jkms.2003.18.2.231>.
- [16] Bonitsis NG, Luong Nguyen LB, LaValley MP, Papoutsis N, Altenburg A, et al. Gender-specific differences in Adamantiades-Behçet's disease manifestations: an analysis of the German registry and meta-analysis of data from the literature. *Rheumatology (Oxford)* 2015;54:121–33, <http://dx.doi.org/10.1093/rheumatology/keu247>.
- [17] Ishido T, Horita N, Takeuchi M, Kawagoe T, Shibuya E, Yamane T, et al. Clinical manifestations of Behçet's disease depending on sex and age: results from Japanese nationwide registration. *Rheumatology (Oxford)* 2017;56:1918–27, <http://dx.doi.org/10.1093/rheumatology/kex285>.
- [18] Chen Y, Cai JF, Lin CH, Guan JL. Demography of vascular Behçet's disease with different gender and age: an investigation with 166 Chinese patients. *Orphanet J Rare Dis* 2019;14:88, <http://dx.doi.org/10.1186/s13023-019-1061-1>.
- [19] Attia DHS, Abdel Noor RA. Severe Behçet's disease equally affects both genders in Egyptian patients: a multicentre retrospective follow-up study. *Reumatismo* 2020;71:218–25, <http://dx.doi.org/10.4081/reumatismo.2019.1223>.
- [20] Li C, Li L, Wu X, Shi J, Liu J, Zhou J, et al. Clinical manifestations of Behçet's disease in a large cohort of Chinese patients: gender- and age-related differences. *Clin Rheumatol* 2020;39:3449–54, <http://dx.doi.org/10.1007/s10067-020-05026-2>.
- [21] Vitale A, Della Casa F, Ragab G, Almaglouth IA, Lopalco G, Pereira RM, et al. Development and implementation of the AIDA International Registry for patients with Behçet's disease. *Intern Emerg Med* 2022;17:1977–86, <http://dx.doi.org/10.1007/s11739-022-03038-1>.
- [22] Floris A, Piga M, Laconi R, Espinosa G, Lopalco G, Serpa Pinto L, et al. Accrual of organ damage in Behçet's syndrome: trajectory, associated factors, and impact on patients' quality of life over a 2-year prospective follow-up study. *Arthritis Res Ther* 2022;24:253, <http://dx.doi.org/10.1186/s13075-022-02947-y>.
- [23] International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. *Lancet* 1990;335:1078–80.
- [24] International Team for the Revision of the International Criteria for Behçet's Disease (ITR-ICBD). The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. *J Eur Acad Dermatol Venereol* 2014;28:338–47, <http://dx.doi.org/10.1111/jdv.12107>.
- [25] Standardization of Uveitis Nomenclature (SUN) Working Group. Classification criteria for Behçet disease uveitis. *Am J Ophthalmol* 2021;228:80–8, <http://dx.doi.org/10.1016/j.ajo.2021.03.058>.
- [26] Kalra S, Silman A, Akman-Demir G, Bohlega S, Borhani-Haghighi A, Constantinescu CS, et al. Diagnosis and management of Neuro-Behçet's disease: international consensus recommendations. *J Neurol* 2014;261:1662–76, <http://dx.doi.org/10.1007/s00415-013-7209-3>.

- [27] Gürler A, Boyvat A, Türsen U. Clinical manifestations of Behçet's disease: an analysis of 2147 patients. *Yonsei Med J* 1997;38:423–7, <http://dx.doi.org/10.3349/ymj.1997.38.6.423>.
- [28] Davatchi F, Shahram F, Chams-Davatchi C, Shams H, Nadji A, Akhlaghi M, et al. Behçet's disease: from East to West. *Clin Rheumatol* 2010;29:823–33, <http://dx.doi.org/10.1007/s10067-010-1430-6>.
- [29] Davatchi F, Shahram F, Chams-Davatchi C, Shams H, Nadji A, Akhlaghi M, et al. Behçet's disease in Iran: analysis of 6500 cases. *Int J Rheum Dis* 2010;13:367–73, <http://dx.doi.org/10.1111/j.1756-185X.2010.01549.x>.
- [30] Zhang Z, He F, Shi Y. Behçet's disease seen in China: analysis of 334 cases. *Rheumatol Int* 2013;33:645–8, <http://dx.doi.org/10.1007/s00296-012-2384-6>.
- [31] Khabbazi A, Noshad H, Shayan FK, Kavandi H, Hajjaliloo M, Kolahi S. Demographic and clinical features of Behçet's disease in Azerbaijan. *Int J Rheum Dis* 2018;21:1114–9, <http://dx.doi.org/10.1111/j.1756-185X.12512>.
- [32] Alpsoy E, Donmez L, Onder M, Gunasti S, Usta A, Karıncaoglu Y, et al. Clinical features and natural course of Behçet's disease in 661 cases: a multicentre study. *Br J Dermatol* 2007;157:901–6, <http://dx.doi.org/10.1111/j.1365-2133.2007.08116.x>.
- [33] Musavian S, Farzaneh R, Rahimi M, Mahdavi AM, Gojazadeh M, Khabbazi A. Validity and reliability of the BODI for assessing damage in Behçet's disease. *Ir J Med Sci* 2023;192:2549–53, <http://dx.doi.org/10.1007/s11845-022-03260-y>.
- [34] Piga M, Floris A, Espinosa G, Serpa Pinto L, Koukias N, Lo Monaco A, et al. Development and preliminary validation of the Behçet's syndrome Overall Damage Index (BODI). *RMD Open* 2020;6:e001192, <http://dx.doi.org/10.1136/rmdopen-2020-001192>.
- [35] Türsen U, Gürler A, Boyvat A. Evaluation of clinical findings according to sex in 2313 Turkish patients with Behçet's disease. *Int J Dermatol* 2003;42:346–51, <http://dx.doi.org/10.1046/j.1365-4362.2003.01741.x>.
- [36] Pipitone N, Boiardi L, Olivieri I, Cantini F, Salvi F, Malatesta R, et al. Clinical manifestations of Behçet's disease in 137 Italian patients: results of a multicenter study. *Clin Exp Rheumatol* 2004;22:S46–51.
- [37] Sota J, Rigante D, Emmi G, Lopalco G, Orlando I, Tosi GM, et al. Behçet's syndrome in Italy: a detailed retrospective analysis of 396 cases seen in 3 tertiary referral clinics. *Intern Emerg Med* 2020;15:1031–9, <http://dx.doi.org/10.1007/s11739-019-02248-4>.
- [38] Davatchi F, Shahram F, Chams-Davatchi C, Sadeghi Abdollahi B, Shams H, Nadji A, et al. Behçet's disease: is there a gender influence on clinical manifestations? *Int J Rheum Dis* 2012;15:306–14, <http://dx.doi.org/10.1111/j.1756-185X.2011.01696.x>.
- [39] Moghaddassi M, Togha M, Shahram F, Hanif H, Dadkhah S, Jahromi SR, et al. Headache in Behçet's disease: types and characteristics. *Springerplus* 2016;5:1077, <http://dx.doi.org/10.1186/s40064-016-2721-4>.
- [40] Alli N, Gur G, Yalcin B, Hayran M. Patient characteristics in Behçet disease: a retrospective analysis of 213 Turkish patients during 2001–4. *Am J Clin Dermatol* 2009;10:411–8, <http://dx.doi.org/10.2165/11310880-000000000-00000>.
- [41] Ideguchi H, Suda A, Takeno M, Ueda A, Ohno S, Ishigatsubo Y. Characteristics of vascular involvement in Behçet's disease in Japan: a retrospective cohort study. *Clin Exp Rheumatol* 2011;29:S47–53.
- [42] Rodríguez-Carballeira M, Alba MA, Solans-Laqué R, Castillo MJ, Ríos-Fernández R, Larrañaga JR, et al. Registry of the Spanish network of Behçet's disease: a descriptive analysis of 496 patients. *Clin Exp Rheumatol* 2014;32:S33–9.
- [43] Daoud F, Rachdi I, Somai M, Zaouak A, Hammami H, Ouederni M, et al. Epidemiological, clinical, and therapeutic characteristics of Behçet's disease: a monocentric study in Tunisia. *Pan Afr Med J* 2021;40:13, <http://dx.doi.org/10.11604/pamj.2021.40.13.19146>.
- [44] Zou J, Luo D, Shen Y, Guan JL. Characteristics and phenotype heterogeneity in late-onset Behçet's syndrome: a cohort from a referral center in China. *Clin Rheumatol* 2021;40:2319–26, <http://dx.doi.org/10.1007/s10067-020-05536-z>.
- [45] Torgutalp M, Sahin Eroglu D, Sezer S, Yayla ME, Karatas G, Uslu Yurteri E, et al. Analysis of vascular involvement in 460 patients with Behçet's syndrome: clinical characteristics and associated factors. *Joint Bone Spine* 2022;89:105277, <http://dx.doi.org/10.1016/j.jbspin.2021.105277>.
- [46] Hou CC, Luo D, Bao HF, Ye JF, Ma HF, Shen Y, et al. Clinical heterogeneity of ocular Behçet's syndrome versus intestinal Behçet's syndrome: a cross-sectional study from Shanghai Behçet's syndrome database. *Arthritis Res Ther* 2022;24:98, <http://dx.doi.org/10.1186/s13075-022-02782-1>.
- [47] Kılıç G, Köroğlu KF, Kumcu MG, Çakır E, Karkucak M, Kılıç E. Gender disparities in Behçet's syndrome: identifying distinct phenotypes through cluster analysis. *Immunol Res* 2024;72:975–81, <http://dx.doi.org/10.1007/s12026-024-09498-1>.
- [48] Gheita TA, El-Latif EA, El-Gazzar II, Samy N, Hammam N, Abdel Noor RA, et al. Behçet's disease in Egypt: a multicenter nationwide study on 1526 adult patients and review of the literature. *Clin Rheumatol* 2019;38:2565–75, <http://dx.doi.org/10.1007/s10067-019-04570-w>.
- [49] Lo Monaco A, La Corte R, Caniatti L, Borrelli M, Trotta F. Neurological involvement in North Italian patients with Behçet disease. *Rheumatol Int* 2006;26:1113–9, <http://dx.doi.org/10.1007/s00296-006-0149-9>.
- [50] Yavuz S, Ozilhan G, Elbir Y, Tolunay A, Eksioğlu-Demiralp E, Direskeneli H. Activation of neutrophils by testosterone in Behçet's disease. *Clin Exp Rheumatol* 2007;25:S46–51.
- [51] Yavuz S, Akdeniz T, Hancer V, Bicakcigil M, Can M, Yanikkaya-Demirel G. Dual effects of testosterone in Behçet's disease: implications for a role in disease pathogenesis. *Genes Immun* 2016;17:335–41, <http://dx.doi.org/10.1038/gene.2016.28>.
- [52] Xu R, Huang F, Wang Y, Liu Q, Lv Y, Zhang Q. Gender- and age-related differences in homocysteine concentration: a cross-sectional study of the general population of China. *Sci Rep* 2020;10:17401.